184 related articles for article (PubMed ID: 24035689)
21. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
[TBL] [Abstract][Full Text] [Related]
22. Understanding and managing methotrexate nephrotoxicity.
Widemann BC; Adamson PC
Oncologist; 2006 Jun; 11(6):694-703. PubMed ID: 16794248
[TBL] [Abstract][Full Text] [Related]
23. l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children.
Etienne MC; Thyss A; Bertrand Y; Touraine R; Rubie H; Robert A; Milano G
J Natl Cancer Inst; 1992 Aug; 84(15):1190-5. PubMed ID: 1635087
[TBL] [Abstract][Full Text] [Related]
24. Fish oil in comparison to folinic acid for protection against adverse effects of methotrexate chemotherapy on bone.
Raghu Nadhanan R; Fan CM; Su YW; Howe PR; Xian CJ
J Orthop Res; 2014 Apr; 32(4):587-96. PubMed ID: 24346859
[TBL] [Abstract][Full Text] [Related]
25. [l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate].
Etienne MC; Thyss A; Bertrand Y; Rubie H; Milano G
Bull Cancer; 1993 Apr; 80(4):357-63. PubMed ID: 8173189
[TBL] [Abstract][Full Text] [Related]
26. Effect of methotrexate and folinic acid on skeletal growth in mice.
Iqbal MP; Ahmed M; Umer M; Mehboobali N; Qureshi AA
Acta Paediatr; 2003 Dec; 92(12):1438-44. PubMed ID: 14971796
[TBL] [Abstract][Full Text] [Related]
27. Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma.
Haran A; Even-Zohar NG; Haran M; Lebel E; Aumann S; Shaulov A; Gatt M; Nachmias B
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):187-193.e1. PubMed ID: 38008594
[TBL] [Abstract][Full Text] [Related]
28. Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice.
Borsi JD; Sagen E; Romslo I; Moe PJ
Pediatr Hematol Oncol; 1990; 7(4):347-63. PubMed ID: 2268535
[TBL] [Abstract][Full Text] [Related]
29. How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis?
Cansu DÜ; Teke HÜ; Bodakçi E; Korkmaz C
Clin Rheumatol; 2018 Dec; 37(12):3419-3425. PubMed ID: 30056523
[TBL] [Abstract][Full Text] [Related]
30. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of methotrexate administration following 5-fluorouracil.
White RM
Am J Clin Oncol; 1996 Oct; 19(5):492-9. PubMed ID: 8823478
[TBL] [Abstract][Full Text] [Related]
32. Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment.
Fan C; Cool JC; Scherer MA; Foster BK; Shandala T; Tapp H; Xian CJ
Bone; 2009 Jan; 44(1):61-70. PubMed ID: 18976724
[TBL] [Abstract][Full Text] [Related]
33. High-dose methotrexate: a critical reappraisal.
Ackland SP; Schilsky RL
J Clin Oncol; 1987 Dec; 5(12):2017-31. PubMed ID: 3316519
[TBL] [Abstract][Full Text] [Related]
34. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
35. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?
Chan BS; Dawson AH; Buckley NA
Clin Toxicol (Phila); 2017 Feb; 55(2):88-96. PubMed ID: 28084171
[TBL] [Abstract][Full Text] [Related]
36. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience.
Garrett AP; Garner EO; Goldstein DP; Berkowitz RS
J Reprod Med; 2002 May; 47(5):355-62. PubMed ID: 12063874
[TBL] [Abstract][Full Text] [Related]
37. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
Winter SS; Dunsmore KP; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Gaynon PS; Borowitz MJ; Loh ML; Rabin KR; Raetz EA; Zweidler-Mckay PA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2018 Oct; 36(29):2926-2934. PubMed ID: 30138085
[TBL] [Abstract][Full Text] [Related]
38. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P
Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509
[TBL] [Abstract][Full Text] [Related]
39. Biochemical and pharmacologic rationale for high-dose methotrexate.
Jolivet J
NCI Monogr; 1987; (5):61-5. PubMed ID: 2448656
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials.
Ortiz Z; Shea B; Suarez-Almazor ME; Moher D; Wells GA; Tugwell P
J Rheumatol; 1998 Jan; 25(1):36-43. PubMed ID: 9458200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]